Ultragenyx Pharmaceutical (RARE) reported a Q4 net loss Thursday of $1.39 per diluted share, narrowing from the loss of $1.52 a year earlier.

Analysts polled by FactSet expected a per-share loss of $1.31.

Revenue in the three months ended Dec. 31 rose to $164.9 million from $127.4 million a year earlier.

Analysts surveyed by FactSet expected $151.9 million.

The company expects 2025 revenue of $640 million to $670 million.

Analysts polled by FactSet expect $642.9 million.